Vestal Point Capital LP Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Vestal Point Capital LP grew its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 14.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 485,000 shares of the company's stock after acquiring an additional 60,000 shares during the period. Vestal Point Capital LP owned about 0.64% of Nurix Therapeutics worth $9,137,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. JPMorgan Chase & Co. grew its holdings in Nurix Therapeutics by 85.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock worth $1,531,000 after acquiring an additional 31,352 shares in the last quarter. Jump Financial LLC purchased a new position in Nurix Therapeutics during the 4th quarter worth $1,406,000. Barclays PLC increased its holdings in shares of Nurix Therapeutics by 77.9% in the 3rd quarter. Barclays PLC now owns 128,344 shares of the company's stock valued at $2,884,000 after purchasing an additional 56,190 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in Nurix Therapeutics by 42.7% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock valued at $14,869,000 after acquiring an additional 235,971 shares during the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in Nurix Therapeutics by 9.3% in the 4th quarter. Affinity Asset Advisors LLC now owns 940,083 shares of the company's stock valued at $17,711,000 after acquiring an additional 79,684 shares during the last quarter.

Nurix Therapeutics Stock Down 2.7%

Shares of NRIX stock traded down $0.27 during trading on Friday, reaching $9.72. 401,505 shares of the company's stock were exchanged, compared to its average volume of 871,857. The stock has a market capitalization of $741.01 million, a PE ratio of -3.36 and a beta of 2.23. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56. The firm's fifty day moving average price is $10.67 and its 200-day moving average price is $16.39.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The firm had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. During the same period in the prior year, the company posted ($0.76) EPS. As a group, analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Insider Activity

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the sale, the insider now owns 61,516 shares of the company's stock, valued at approximately $707,434. This trade represents a 5.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 2,438 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $28,037.00. Following the completion of the transaction, the chief financial officer now owns 39,922 shares in the company, valued at $459,103. This represents a 5.76% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,838 shares of company stock valued at $221,500. Company insiders own 7.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on NRIX. Leerink Partnrs raised shares of Nurix Therapeutics to a "hold" rating in a research report on Monday, March 17th. JPMorgan Chase & Co. dropped their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Stifel Nicolaus dropped their price target on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Morgan Stanley boosted their target price on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a research note on Monday, February 3rd. Finally, HC Wainwright reissued a "buy" rating and set a $36.00 price target on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, Nurix Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $30.44.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.